Evidence map›Paper›PMID 36588582›Full record

ArticleCancer research communications2022

Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade.

Gabriel Abril-Rodríguez, Davis Y Torrejon, Daniel Karin, Katie M Campbell, Egmidio Medina, Justin D Saco, Mildred Galvez, Ameya S Champhekar, Ivan Perez-Garcilazo, Ignacio Baselga-Carretero and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Gabriel Abril-RodríguezDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Davis Y TorrejonDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Daniel KarinDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Katie M CampbellDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Egmidio MedinaDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Justin D SacoDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Mildred GalvezDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Ameya S ChamphekarDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Ivan Perez-GarcilazoDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Ignacio Baselga-CarreteroDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Jas SinghArcus Biosciences, Inc., Hayward, CA.
Begoña Comin-AnduixDepartment of Surgery, Division of Surgical Oncology, UCLA.
Cristina Puig-SausDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
Antoni RibasDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA).
University of California, Los Angeles · USPulse Biosciences (United States) · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
NCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009056NCI NIH HHS T32 CA009120NIAID NIH HHS P30 AI028697NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

PAK4 inhibition can sensitize tumors to immune checkpoint blockade (ICB) therapy, however, the underlying mechanisms remain unclear. We report that PAK4 inhibition reverses immune cell exclusion by increasing the infiltration of CD8 T cells and CD103

Indexed as

Immune Checkpoint InhibitorsMelanomaAnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesMiceTumor MicroenvironmentAntigens, NeoplasmImmune Checkpoint Inhibitors

Identifiers

PMID36588582
PMCPMC9799984
OpenAlexW4295678817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.